Kenvue Inc.: World Leader in Consumer Healthcare Products

Kenvue Inc. is a consumer healthcare product manufacturer and marketer. The company offers self-care, personal care, and beauty and skin care products under brands such as Zyrtec, Benadryl, Zarbee's, Neutrogena, and Aveeno. Net sales are primarily generated in North America (49.3%), with a smaller portion in Europe-Middle East-Africa (21.9%), Asia-Pacific (20.1%), and Latin America (8.7%).

Kenvue Inc. (NYSE: KVUE), a leading consumer healthcare company, is set to report its Q3 2025 earnings on November 6. According to financial analysts, the company is expected to post an earnings per share (EPS) of $0.27, a decrease from the $0.28 reported in the same quarter last year Here's How You Can Earn $100 In Passive Income By Investing In Kenvue Stock^[1]. The quarterly revenue is anticipated to be $3.86 billion, down from $3.90 billion in the prior-year period Here's How You Can Earn $100 In Passive Income By Investing In Kenvue Stock^[1].

The company's stock has been trading within a 52-week range of $17.15 to $25.17, and the dividend yield currently stands at 4.58%. Kenvue paid $0.83 per share in dividends during the last 12 months Here's How You Can Earn $100 In Passive Income By Investing In Kenvue Stock^[1]. To earn $100 per month from Kenvue dividends, an investor would need to own approximately 1,420 shares at a price of $18.45 each Here's How You Can Earn $100 In Passive Income By Investing In Kenvue Stock^[1].

Kenvue's product portfolio includes well-known brands such as Tylenol, Listerine, and Neutrogena, covering categories like pain management, skin and beauty, oral care, and cough, cold, and allergy care. The company's net sales are primarily generated in North America (49.3%), followed by Europe-Middle East-Africa (21.9%), Asia-Pacific (20.1%), and Latin America (8.7%) Kenvue CEO Sough to Prevent RFK Jr. From Citing Tylenol as Potential Autism Cause^[2].

The company's CEO has been actively seeking to prevent RFK Jr. from citing Tylenol as a potential cause of autism, highlighting the company's commitment to product safety and transparency Kenvue CEO Sough to Prevent RFK Jr. From Citing Tylenol as Potential Autism Cause^[2]. Kenvue's CFO, Amit Banati, has adjusted the company's outlook for 2025, reflecting the year-to-date results and current expectations for the second half of the year. The company expects net sales and organic sales to be down by a low single digit for the full-year 2025 Here's How You Can Earn $100 In Passive Income By Investing In Kenvue Stock^[1].

Investors should closely monitor Kenvue's earnings report for insights into the company's performance and future prospects. The earnings report will provide valuable information on the company's ability to navigate the dynamic external environment and deliver sustainable value to shareholders.